Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
Disc Medicine (NASDAQ:IRON) reported updated clinical data at the 2026 EHA meeting in Stockholm. In RALLY-MF, DISC-0974 showed durable overall anemia responses in myelofibrosis across subgroups, including 55% major hemoglobin response in non-transfusion dependent patients and transfusion independence in 64% (TD Low) and 50% (TD High). In HELIOS, bitopertin sustained PPIX reductions and improved light tolerance with favorable longer-term safety. A corporate call is set for June 15.
How this was made
The 30-second read
Why it matters
The newest concrete facts are the quantified durability/response rates in RALLY-MF subgroups (including transfusion independence and hepcidin/iron changes) and sustained PPIX reduction/light tolerance improvements with favorable longer-term safety in HELIOS, alongside stated regulatory/Phase 3 timing (EoP2 with FDA by end of 2026; APOLLO Phase 3 readout in Q4; RESTORE-PV initial data expected in Q4 2026).
Market read
Traders may reprice IRON’s clinical probability and timing into the June 15 corporate update call and later Q4 regulatory/Phase 3 catalysts based on the specific durability and subgroup efficacy figures disclosed.
What to watch
Market may focus on endpoint translation to registrational acceptance (e.g., how EoP2/CRL response criteria map to these subgroup response rates) rather than headline response percentages alone.
Background
Disc Medicine is presenting updated clinical data at the 2026 EHA Annual Meeting for three investigational programs: DISC-0974 (RALLY-MF, myelofibrosis with anemia), bitopertin (HELIOS extension, erythropoietic protoporphyria), and DISC-3405 (RESTORE-PV, polycythemia vera).
Ticker impact
Disc Medicine reports updated Phase 2 RALLY-MF anemia response data for DISC-0974 and HELIOS extension safety/efficacy updates for bitopertin, plus upcoming FDA and APOLLO milestones.
Bias toward upside/volatility into the June 15 call and later Q4 catalysts, assuming market had not fully priced these specific updated response rates.
The article provides multiple quantified efficacy outcomes (anemia response, transfusion independence, PPIX/light tolerance durability) and ties them to concrete next steps (EoP2 with FDA by year-end; APOLLO Phase 3 readout in Q4; potential CRL response basis).
Market effects
Reinforces investor appetite for hematology/erythropoiesis and heme/iron-homeostasis mechanisms; may modestly lift sentiment for small-cap clinical-stage biopharma around EHA data cycles.
Primarily US-listed biotech sentiment; EHA Stockholm timing can drive Europe-to-US spillover in premarket/early session trading.
EHA conference updates can influence global biotech positioning and peer read-across for anemia/EPP endpoints and durability expectations.
Counterpoint
Open-label Phase 2 data and extension follow-up may not fully de-risk efficacy vs placebo/standard-of-care; durability claims still need Phase 3 confirmation.
Key entities
- companyDisc Medicine
Clinical-stage biopharmaceutical company presenting updated Phase 2/extension data at EHA and outlining upcoming FDA/Phase 3 milestones.
- clinical_programDISC-0974 (RALLY-MF)
Phase 2 open-label study in myelofibrosis with anemia; updated subgroup response and transfusion-independence outcomes reported.
- clinical_programbitopertin (HELIOS)
Phase 2 open-label extension in erythropoietic protoporphyria; updated durability of PPIX reduction and light tolerance with longer-term safety.
- clinical_programAPOLLO
Phase 3 program for bitopertin; article states Q4 readout could support CRL response and potential traditional approval if successful.
